15 résultats
FIELD OF THE INVENTION
The present invention relates to new products, namely polysaccharidic esters of N-derivatives of glutamic acid (N-GA). Their use as antiproliferatives in pharmaceutics is herein described.
PRIOR ART
Several modified polysaccharides have been described in the art. They are
FIELD OF THE INVENTION
This invention relates to methods for treating joint pain associated with inflammatory, degenerative and other joint diseases.
BACKGROUND OF THE INVENTION
Over 20 million people in the United States suffer from degenerative joint diseases. This results in over 2 million
CROSS-REFERENCES TO RELATED APPLICATION
This patent application claims the benefit of priority from Korean Patent Application No. 2012-0037414, filed on Apr. 10, 2012 in the Korean Intellectual Property Office (KIPO), the entire contents of which are incorporated herein by reference.
BACKGROUND OF
This invention relates to amino acid derivatives, and more particularly to amino acid derivatives which possess anti-cholecystokinin activity. The invention also relates to methods for preparing such cholecystokinin antagonists and to compounds which are useful as intermediates in such
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is filed under the provisions of 35 U.S.C. .sctn.371 and claims the priority of International Patent Application No. PCT/KR2005/003632 filed on 31 Oct. 2005 entitled "Hyaluronidase Inhibitor Containing Poly-Gamma-Glutamic Acid As An Effective
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a U.S. national phase under the provisions of 35 U.S.C. .sctn.371 of International Patent Application No. PCT/KR12/02189 filed Mar. 26, 2012, which in turn claims priority of Korean Patent Application No. 10-2012-00069366 filed Jan. 19,
FIELD OF THE INVENTION
This invention concerns a new family of peptide molecules having the capacity especially of stimulating the expression of the cytokines of inflammation and promoting regeneration of tissues. The invention, thus, also pertains to pharmaceutical compositions containing at least
This invention relates to the treatment and prophylaxis of sepsis, septic shock and other life-threatening inflammatory conditions.
The mortality of systemic bacterial infection (bacteraemia) is high, particularly for gram-negative infections, where mortality levels are still comparable to those of
FIELD OF THE INVENTION
The invention generally relates to treatments for abnormal cell proliferation, particularly for treating epidermal disorders, and more particularly relates to a method of inhibiting abnormal cell growth with the use of certain corticotropin-releasing hormone ("CRH") analogs.
FIELD OF THE INVENTION
The invention generally relates to treatments for abnormal cell proliferation, particularly for treating epidermal disorders, and more particularly relates to a method of inhibiting abnormal cell growth with the use of certain corticotropin-releasing hormone ("CRH") analogs.
BACKGROUND OF THE INVENTION
Clostridium botulinum produces seven different neurotoxins (BoNTs) which differentiated serologically by the lack of anti-serum cross serotype neutralization. BoNTs are the most potent toxins known to humans and are the causative agents of the disease botulism (1). BoNTs
FIELD OF THE INVENTION
This invention relates to the field of atherosclerosis. In particular, this invention pertains to the identification of a class of peptides that are orally administrable and that ameliorate one or more symptoms of atherosclerosis.
BACKGROUND OF THE INVENTION
Cardiovascular
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a U.S. national phase under the provisions of 35 U.S.C. .sctn.371 of International Patent Application No. PCT/KR11/05206 filed Jul. 14, 2011, which in turn claims priority of Korean Patent Application No. 10-2010-0067710 filed Jul. 14,
The present invention relates to amide derivatives of p-isobutyl-phenyl-propionic acid, having general formula: ##STR2## wherein X represents the radical of a substituted amine selected amongst lysine, metatrifluorotoluidine, glutamic acid and aspartic acid.
The anti-inflammatory properties of
FIELD OF THE INVENTION
The present invention relates to glycopeptide compositions containing a glycoside and a peptide and their uses as biomaterials. Specific embodiments relate to chitosan-based glycopeptides. More specific embodiments relate to glycopeptides including chitosan and poly(amino